Therapy for hepatitis C genotype 3: moving forward

Journal of Viral Hepatitis

Volumn 22, Issue 9, 2015, Pages 683-690

  Buti, M ^a,b   Llaneras, J ^a   Riveiro Barciela, M ^a   Esteban, R ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

daclatasvir; direct acting antiviral; genotype 3; hepatitis C; sofosbuvir; treatment

Indexed keywords

ALISPORIVIR; DACLATASVIR; GRAZOPREVIR; GS 5816; LEDIPASVIR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; SOFOSBUVIR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; DATA ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION TEST KIT; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RELAPSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS IDENTIFICATION; VIRUS RESISTANCE; ADVERSE EFFECTS; CLASSIFICATION; DRUG COMBINATION; ECONOMICS; GENETICS; GENOTYPE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; PROCEDURES; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; RIBAVIRIN; SOFOSBUVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84936847638     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12419     Document Type: Article

References (30)

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60 (2): 392-420.
2. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49 (4): 1335-1374.
3. AASLD. Recommendations for Testing, Managing, and Treating Hepatitis C. AASLD, 2014. http://www.hcvguidelines.org (accessed 5 February 2015)
4. Sovaldi: EPAR- product information. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002798/human-med-001723.jsp&mid=WC0b01ac058001d124 (accessed 2 February 2015).
5. Daklinza: EPAR: product information. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003768/human-med-001792.jsp&-mid=WC0b01ac058001d124 (accessed 3 February 2015).
6. Harvoni: EPAR- product information. 2014. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003850/human-med-001813.jsp&mid=WC0b01ac058001d124 (accessed 3 February 2015).
7. Lawitz E, Gane EJ,. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 369 (7): 678-679.
8. Jacobson IM, Gordon SC, Kowdley KV, et al,. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368 (20): 1867-1877.
9. Marcellin P, Cheinquer H, Curescu M, et al,. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012; 56 (6): 2039-2050.
10. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S,. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55 (1): 69-75.
11. Di Martino V, Richou C, Cervoni JP, et al,. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology 2011; 54 (3): 789-800.
12. Shoeb D, Dearden J, Weatherall A, et al,. Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial. J Hepatol 2014; 60 (4): 699-705.
13. Gane EJ, Stedman CA, Hyland RH, et al,. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368 (1): 34-44.
14. Lawitz E, Lalezari JP, Hassanein T, et al,. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13 (5): 401-408.
15. Lawitz E, Poordad F, Brainard DM, et al,. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology 2015; 61 (3): 769-775.
16. Pelosi LA, Voss S, Liu M, Gao M, Lemm JA,. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother 2012; 56 (10): 5230-5239.
17. Hezode C, Hirschfield GM, Ghesquiere W, et al,. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2014; doi: 10.1136/gutjnl-2014-307498. [Epub ahead of print]
18. Dore GJ, Lawitz E, Hezode C, et al,. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology 2015; 148 (2): 355-366 e1.
19. Zeuzem S, Dusheiko GM, Salupere R, et al,. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370(21): 1993-2001.
20. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al,. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370 (3): 211-221.
21. Nelson DR, Cooper JN, Lalezari JP, et al,. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study. Hepatology 2015; 61 (4): 1127-1135.
22. Esteban R, Lalezari J, Ni L, et al,. Successful Retreatment with Sofosbuvir-containing regimens for HCV genotype 2 or 3 infected patients who failed prior sofosbuvir plus ribavirin therapy. J Hepatol 2014; 60 (1): S4-S5.
23. Gane EJHR, An D, Pang PS, Symonds WT, Mchutchison JG, Stedman CA,. Sofosbuvir/Ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients and genotype-1 patients with prior sofosbuvir treatment experience. J Hepat 2014; 60: S3-S4.
24. Harvoni recommended for the treatment of chronic hepatitis C. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2014/09/news-detail-002175.jsp&mid=WC0b01ac058004d5c1 (accessed 4 May 2015).
25. Foster GR, Pianko S, Cooper C, Brown A, Forton D, Nahass RG, George J, Barnes E, Brainard DM, Massetto B, Lin M, McHutchison JG, Subramanian GM, Agarwal K,. Sofosbuvir + PegInterferon/Ribavirin for 12 weeks vs Sofosbuvir + Ribavirin for 16 or 24 weeks in Genotype 3 HCV infected patients and treatment-experienced cirrhotic pacientes with genotype 2 HCV: The BOSON study. J Hepatol. 2015; 62: S259-S260.
26. Cheng GYM, Peng B, Lee YJ, et al,. GS-5816, a second generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage and a high resistance barrier. J Hepatol 2013; 58: S484-S485.
27. Gane EJHR, An D, McNally J, et al,. Once daily sofosbuvir with GS-5816 for 8 weeks with or without ribavirin in patients with HCV genotype 3 without cirrhosis result in high rates of SVR12: the ELECTRON2 study. Hepatology 2014; 60 (S1): 236A-237A.
28. Pawlotsky JMSS, Foster G, Peng CY, Rasenack J, Flisiak R,. Alisporivir plus ribavirin is highly effective interferon-free or interferon-add-on regimen in previously untreated HCV-GT2 or GT3 patients: SVR12 results from VITAL-1 phase 2B study. J Hepatol 2012; 56 (2): S553.
29. Lawitz E, Sullivan G, Rodriguez-Torres M, et al,. Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. J Infect 2015; 70 (2): 197-205.
30. Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Infection (MK-3682-011). Available at: https://clinicaltrials.gov/ct2/show/NCT02332707 (accessed 3 February 2015).